Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and AggressivenessVivek Patel, Tsun Leung Chan, Julian Adlard et al.|Cancer Research|2019Cited by 53
Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23).Giovanni Scambia, Domenica Lorusso, Francesco Raspagliesi et al.|Journal of Clinical Oncology|2022Cited by 6
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With <i>BRCA</i>-Mutated and/or BRCAness Phenotype: A Randomized Phase III TrialDomenica Lorusso, Giovanni Scambia, Francesco Raspagliesi et al.|Journal of Clinical Oncology|2024Cited by 3